Zobrazeno 1 - 10 of 375 pro vyhledávání: '"O. Stern"'
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection
Autor: Shuhei Nishiguchi, Kristi L. Berger, Atsushi Taniguchi, Jerry O. Stern, Keiko Suzaki, Joseph Scherer, Yasuhisa Urano, Masao Omata, Anne-Marie Quinson
Publikováno v: Hepatology Research. 47:E142-E151
AIM We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection. METHODS Treatment-naiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54551e666cfe05ffa1b717a7891e7f12
https://doi.org/10.1111/hepr.12741
Zobrazit plný text záznamu
6
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
Autor: Federico J. Mensa, Jerry O. Stern, Vicente Soriano, Maria Buti, Jawahar Taunk, Jean-François Dufour, Richard Vinisko, Parvez S. Mantry, Wulf O. Böcher, John-Paul Gallivan, Robert Buynak, Stefan Zeuzem
Publikováno v: Liver International. 35:417-421
BACKGROUND & AIMS The safety and efficacy of the interferon-free combination of faldaprevir (NS3/A4 protease inhibitor), deleobuvir (BI 207127, non-nucleoside polymerase inhibitor), and ribavirin in treatment-naive patients chronically infected with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c02c53a983569080093b917d954db7b
https://doi.org/10.1111/liv.12693
Zobrazit plný text záznamu
7
Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients
Autor: Lalitha Podila, Rucha S. Sane, Qihong Huang, Jerry O. Stern, Yongmei Li, Tarik Asselah, G. Steinmann, Gerhard Nehmiz, Wulf O. Böcher, Mitchell E. Taub, Stephen Olson, Kirsten Mease, Donald J. Tweedie
Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 351:403-412
Faldaprevir, an investigational agent for hepatitis C virus treatment, is well tolerated but associated with rapidly reversible, dose-dependent, clinically benign, unconjugated hyperbilirubinemia. Multidisciplinary preclinical and clinical studies we
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082ed1b2129063a58afc005005249cbd
https://doi.org/10.1124/jpet.114.218081
Zobrazit plný text záznamu
8
Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir
Autor: Mireille Cartier, Gerhard G. Steinmann, George Kukolj, Jerry O. Stern, Kristi L. Berger, Joseph Scherer, Wulf O. Böcher, Marie-Josée Massariol, Yakov Datsenko, Ibtissem Triki, Martin Marquis
Publikováno v: Antimicrobial Agents and Chemotherapy. 58:698-705
A challenge to the treatment of chronic hepatitis C with direct-acting antivirals is the emergence of drug-resistant hepatitis C virus (HCV) variants. HCV with preexisting polymorphisms that are associated with resistance to NS3/4A protease inhibitor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd3cf07fb110ae329652da0f0c543634
https://doi.org/10.1128/aac.01976-13
Zobrazit plný text záznamu
9
SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
Autor: Thomas Berg, Yakov Datsenko, Tarik Asselah, Peter Ferenci, Stefan Mauss, Marcus Schuchmann, Wulf O. Böcher, Andreas Maieron, Dominique Larrey, Jerry O. Stern, Melek Ozan, Douglas T. Dieterich, Gerhard G. Steinmann, Vlad Ratziu, Dominique Guyader
Publikováno v: Antimicrobial Agents and Chemotherapy
Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated interferon α-2a and ribavirin (PegIFN/RBV) in treatment-naive patients in a prior study (SILEN-C1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896a626c06982afb9bd032bbd4647274
http://europepmc.org/articles/PMC4068493
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje